Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University Hospital, Kirrberger Str., IMED, 66421, Homburg/Saar, Germany.
Herz. 2021 Jun;46(3):228-233. doi: 10.1007/s00059-020-05011-0. Epub 2021 Jan 4.
Valvular heart disease (VHD) is common in patients with impaired renal function, especially in those with end-stage renal disease (ESRD) undergoing dialysis. Progressive sclerosis and calcification of the valves and valvular annuli are major components of the etiology. These processes typically affect the aortic and mitral valve and can lead to both valvular insufficiency and stenosis. As recommended by the 2017 ESC/EACTS Guidelines for the management of VHD, surgical treatment remains the standard care for most cases of severe VHD. However, chronic kidney disease (CKD) is associated with increased mortality when compared with patients with preserved renal function. Interventional treatment options have emerged as an effective and safe alternative for patients older than 75 years and/or with increased surgical risk. Consequently, in patients with CKD at increased surgical risk who have suitable anatomical morphology, transcatheter replacement and/or repair should be discussed in the interdisciplinary "heart team."
瓣膜性心脏病(VHD)在肾功能受损的患者中很常见,尤其是在接受透析的终末期肾病(ESRD)患者中。瓣膜和瓣环的进行性硬化和钙化是病因的主要组成部分。这些过程通常会影响主动脉瓣和二尖瓣,并导致瓣膜关闭不全和狭窄。根据 2017 年 ESC/EACTS 瓣膜性心脏病管理指南的建议,手术治疗仍然是大多数严重 VHD 病例的标准治疗方法。然而,与肾功能正常的患者相比,慢性肾脏病(CKD)会导致死亡率增加。介入治疗选择已成为 75 岁以上和/或手术风险增加的患者的有效和安全替代方案。因此,对于手术风险增加的 CKD 患者,如果具有合适的解剖形态,则应在跨学科的“心脏团队”中讨论经导管置换和/或修复。